Improving cancer treatment for gastric and lung cancers using new tumor models.
Official title: Bioinformatics Core
Funded at University of California at Davis · NIH-10896238 · Data updated 2026-11-12
This study is working to improve cancer treatments for gastric and lung cancers by creating new models from tumors of minority patients, so doctors can find the best targeted therapies that match each person's unique cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $38,149 |
| NIH project number | 5U54CA283766-02 |
| Project ID | NIH-10896238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with gastric or lung cancers, particularly those from minority backgrounds.
✕Less likely to help
Patients with cancers other than gastric or lung cancers may not benefit from this research.
What this research studies
This research focuses on enhancing precision medicine for gastric and lung cancers by developing and characterizing over 120 new patient-derived xenograft (PDX) tumor models from minority populations. These models will be used in laboratory and pre-clinical trials to evaluate the effectiveness of targeted therapies tailored to the molecular profiles of individual tumors. The project will involve extensive data analysis to correlate treatment responses with the unique characteristics of each tumor, aiming to optimize therapeutic strategies for better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients with gastric and lung cancers.
How similar studies have gone: Previous research has shown promise in using patient-derived tumor models for developing targeted cancer therapies, indicating a strong potential for success in this approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Tepper, Clifford G — University of California at Davis
- Study coordinator: Tepper, Clifford G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.